Long-term response to second-line afatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Analysis of the LUX-Head & Neck 1 (LHN1) trial

Autor:	K. Hoermann, J. Fayette, J-P. Machiels, L. de Souza Viana, A. Izmailov, V. Vladimirov, G. De Castro, C. Le Tourneau, Ulisses Ribaldo Nicolau, K. Okami, E. Zografos, Nicholas F. Dupuis, R. Galiulin, Lisa Licitra, Eric P. Cohen, Robert I. Haddad, Makoto Tahara, E. Ehrnrooth, J. Love
Rok vydání:	2017
Předmět:	Oncology medicine.medical_specialty business.industry Afatinib Head neck Hematology medicine.disease Head and neck squamous-cell carcinoma Second line Internal medicine Medicine In patient business medicine.drug
Zdroj:	Annals of Oncology. 28:v386
ISSN:	0923-7534
DOI:	10.1093/annonc/mdx374.035
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::18bd396fcacb927b7272df5c5dc96716 https://doi.org/10.1093/annonc/mdx374.035 Zobrazit plný text záznamu